An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome

BACKGROUND: Lenalidomide is an effective new agent for the treatment of patients with myelodysplastic syndrome (MDS), an acquired hematopoietic disorder characterized by ineffective blood cell production and a predisposition to the development of leukemia. Patients with an interstitial deletion of C...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Ebert, Benjamin L, Galili, Naomi, Tamayo, Pablo, Bosco, Jocelyn, Mak, Raymond, Pretz, Jennifer, Tanguturi, Shyam, Ladd-Acosta, Christine, Stone, Richard, Golub, Todd R, Raza, Azra
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2008
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2235894/
https://ncbi.nlm.nih.gov/pubmed/18271621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pmed.0050035
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items